{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T23:17:51Z","timestamp":1777936671428,"version":"3.51.4"},"reference-count":44,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Clin Med Insights Oncol"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Non-Hodgkin Lymphoma (NHL) is an increasingly prevalent hematological malignancy in Egypt, highlighting the need for a better understanding of its genetic risk factors. The TP53 and MDM4 genes play critical roles in cellular homeostasis and cancer development. This study aimed to assess the frequency of the TP53 (SNP rs1042522) Arg72Pro and MDM4 (SNP rs4245739) A\u2009&gt;\u2009C polymorphisms as potential risk factors for NHL in adult Egyptian patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A case-control study was conducted involving 80 adult NHL patients and 100 control age- and sex-matched healthy controls. Genotyping for the TP53 (rs1042522) Arg72Pro and MDM4 (rs4245739) A\u2009&gt;\u2009C polymorphisms was performed using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A significant association was found between the homozygous TP53 Pro\/Pro genotype and increased susceptibility to NHL (47.5% in patients vs 4.0% in controls;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009&lt;\u2009.001), as well as a higher frequency of the mutant C allele among NHL cases (63.8% vs 28.0%;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009&lt;\u2009.001). In contrast, no significant association was observed between MDM4 polymorphisms and NHL risk. In addition, analysis of treatment outcomes revealed no statistically significant differences in overall survival or progression-free survival based on TP53 or MDM4 genotypes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>These findings suggest that the TP53 Arg72Pro polymorphism is a significant genetic marker for NHL susceptibility in the Egyptian population, while MDM4 polymorphisms do not appear to contribute to disease risk. Further studies are warranted to elucidate the genetic mechanisms underlying NHL and to explore their implications for risk stratification and therapeutic strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/11795549251352047","type":"journal-article","created":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T07:46:57Z","timestamp":1751528817000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Contribution of TP53 and MDM4 Genetic Polymorphisms as a Risk Factor in Non-Hodgkin Lymphoma in Adult Egyptian Patients"],"prefix":"10.1177","volume":"19","author":[{"given":"Eman A","family":"Helal","sequence":"first","affiliation":[{"name":"Molecular and Cell Biology, Zoology Department, Faculty of Science, Cairo University, Cairo, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naglaa M","family":"Hassan","sequence":"additional","affiliation":[{"name":"Clinical Pathology Department, National Cancer Institute, Cairo University, Cairo, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0264-3096","authenticated-orcid":false,"given":"Mahmoud M","family":"Kamel","sequence":"additional","affiliation":[{"name":"Clinical Pathology Department, National Cancer Institute, Cairo University, Cairo, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahmoud A","family":"Amer","sequence":"additional","affiliation":[{"name":"Molecular and Cell Biology, Zoology Department, Faculty of Science, Cairo University, Cairo, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roxan E","family":"Shafik","sequence":"additional","affiliation":[{"name":"Clinical Pathology Department, National Cancer Institute, Cairo University, Cairo, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,7,3]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.20107"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-06-1056"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/ng.626"},{"key":"e_1_3_3_5_2","volume-title":"Cancer Pathology Registry 2020","author":"El Bolkainy MN","year":"2022","unstructured":"El Bolkainy MN, Nouh MA, El-Bolkainy TN. Cancer Pathology Registry 2020. Cairo National Cancer Institute; 2022."},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.cej.0000236262.52273.88"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mpmed.2019.11.001"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-021-02396-8"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2019.07.001"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.13483"},{"key":"e_1_3_3_11_2","first-page":"45","article-title":"TP53 polymorphisms and risk of non-Hodgkin lymphoma: a meta-analysis","volume":"12","author":"Liu Y","year":"2022","unstructured":"Liu Y, Zhang J, Chen Y, et al. TP53 polymorphisms and risk of non-Hodgkin lymphoma: a meta-analysis. Blood Cancer J. 2022;12:45-52.","journal-title":"Blood Cancer J"},{"key":"e_1_3_3_12_2","article-title":"The functional TP53 rs1042522 and MDM4 rs4245739 genetic variants contribute to non-Hodgkin lymphoma risk","volume":"9","author":"Fan C","year":"2014","unstructured":"Fan C, Wei J, Yuan C, et al. The functional TP53 rs1042522 and MDM4 rs4245739 genetic variants contribute to non-Hodgkin lymphoma risk. PLoS ONE. 2014;9:e107047.","journal-title":"PLoS ONE"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.25710"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21834"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.595187"},{"key":"e_1_3_3_16_2","first-page":"89","article-title":"MDM4 polymorphisms and their association with cancer risk: a review","volume":"11","author":"P\u00e9rez C","year":"2020","unstructured":"P\u00e9rez C, Zhang Y, Liu F, et al. MDM4 polymorphisms and their association with cancer risk: a review. Front Genet. 2020;11:89.","journal-title":"Front Genet"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1235122"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.12326"},{"key":"e_1_3_3_19_2","first-page":"123","article-title":"Genetic polymorphisms in TP53 and MDM4 genes as biomarkers for cancer risk","volume":"12","author":"Hussain M","year":"2020","unstructured":"Hussain M, Patel A, Rahman A, et al. Genetic polymorphisms in TP53 and MDM4 genes as biomarkers for cancer risk. J Cancer Res. 2020;12:123-130.","journal-title":"J Cancer Res"},{"key":"e_1_3_3_20_2","first-page":"75","article-title":"The role of genetic factors in the susceptibility to non-Hodgkin lymphoma","volume":"46","author":"Salih NK","year":"2021","unstructured":"Salih NK, El-Sayed Y, Mahran S, et al. The role of genetic factors in the susceptibility to non-Hodgkin lymphoma. Egypt J Hematol. 2021;46:75-82.","journal-title":"Egypt J Hematol"},{"key":"e_1_3_3_21_2","volume-title":"Basic and Clinical Biostatistics","author":"Dawson-Saunders B","year":"1994","unstructured":"Dawson-Saunders B, Trapp RG, eds. Basic and Clinical Biostatistics. Lange Medical Books, Appleton & Lange; 1994."},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrm1546"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3430"},{"key":"e_1_3_3_24_2","first-page":"5322","article-title":"p53 and survival in diffuse large B-cell lymphoma: molecular and clinicopathologic correlations","volume":"119","author":"Xu-Monette ZY","year":"2012","unstructured":"Xu-Monette ZY, Wu L, Visco C, et al. p53 and survival in diffuse large B-cell lymphoma: molecular and clinicopathologic correlations. Blood. 2012;119:5322-5334.","journal-title":"Blood"},{"key":"e_1_3_3_25_2","first-page":"863","article-title":"TP53 and human cancer","volume":"9","author":"Baker SJ","year":"2009","unstructured":"Baker SJ, Markowitz S, Fearon ER, Willson JK, Vogelstein B. TP53 and human cancer. Nat Rev Cancer. 2009;9:863-873.","journal-title":"Nat Rev Cancer"},{"key":"e_1_3_3_26_2","first-page":"4983","article-title":"Functional polymorphisms in the TP53 gene","volume":"68","author":"Liu G","year":"2008","unstructured":"Liu G, Parant JM, Lang G, et al. Functional polymorphisms in the TP53 gene. Cancer Res. 2008;68:4983-4988.","journal-title":"Cancer Res"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2584"},{"key":"e_1_3_3_28_2","first-page":"323","article-title":"Polymorphisms in the TP53 gene and risk of lymphomas: a meta-analysis","volume":"53","author":"Hernandez AC","year":"2012","unstructured":"Hernandez AC, Cantu DE, Paniagua M, et al. Polymorphisms in the TP53 gene and risk of lymphomas: a meta-analysis. Leuk Lymphoma. 2012;53:323-331.","journal-title":"Leuk Lymphoma"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0045820"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2011.04.001"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-8-116"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1272876"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17971"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3760-0"},{"key":"e_1_3_3_35_2","article-title":"The correlation of mouse double minute 4 (MDM4) polymorphisms (rs4245739, rs1563828, rs11801299, rs10900598, and rs1380576) with cancer susceptibility: a meta-analysis","volume":"29","author":"Chen J","year":"2023","unstructured":"Chen J, Li X, Liu R, et al. The correlation of mouse double minute 4 (MDM4) polymorphisms (rs4245739, rs1563828, rs11801299, rs10900598, and rs1380576) with cancer susceptibility: a meta-analysis. Med Sci Monit. 2023;29:e935671.","journal-title":"Med Sci Monit"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-013-2615-x"},{"key":"e_1_3_3_37_2","article-title":"Association of a genetic variation in a miR-191 binding site in MDM4 with risk of esophageal squamous cell carcinoma","volume":"8","author":"Zhou L","year":"2013","unstructured":"Zhou L, Zhang X, Li Z, et al. Association of a genetic variation in a miR-191 binding site in MDM4 with risk of esophageal squamous cell carcinoma. PLoS ONE. 2013;8:e64331.","journal-title":"PLoS ONE"},{"key":"e_1_3_3_38_2","article-title":"A regulatory MDM4 genetic variant locating in the binding sequence of multiple microRNAs contributes to susceptibility of small cell lung cancer","volume":"10","author":"Gao F","year":"2015","unstructured":"Gao F, Xiong X, Pan W, et al. A regulatory MDM4 genetic variant locating in the binding sequence of multiple microRNAs contributes to susceptibility of small cell lung cancer. PLoS ONE. 2015;10:e0135647.","journal-title":"PLoS ONE"},{"key":"e_1_3_3_39_2","first-page":"1217","article-title":"Association between single nucleotide polymorphism at miR-191 target site and susceptibility to gastric cancer","volume":"30","author":"Feng JB","year":"2014","unstructured":"Feng JB, Nie YQ, Lin Y, Li YF, Du YL. Association between single nucleotide polymorphism at miR-191 target site and susceptibility to gastric cancer. J Pract Med. 2014;30:1217-1220. [In Chinese]","journal-title":"J Pract Med"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.555"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13277-016-4940-2"},{"key":"e_1_3_3_42_2","article-title":"MDM2 and MDM4: p53 antagonists","volume":"1","author":"Marine JC","year":"2010","unstructured":"Marine JC, Lozano G. MDM2 and MDM4: p53 antagonists. Cold Spring Harb Perspect Med. 2010;1:a000970.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"e_1_3_3_43_2","first-page":"1276","article-title":"Impact of TP53 mutations on clinical outcomes in patients with acute myeloid leukemia","volume":"132","author":"Kim HJ","year":"2018","unstructured":"Kim HJ, Kim YK, Lee JH, et al. Impact of TP53 mutations on clinical outcomes in patients with acute myeloid leukemia. Blood. 2018;132:1276-1285.","journal-title":"Blood"},{"key":"e_1_3_3_44_2","first-page":"100","article-title":"Mutant p53 enhances metastasis and alters tumor metabolism","volume":"176","author":"Muller PAJ","year":"2016","unstructured":"Muller PAJ, Vousden KH, Norman JC. Mutant p53 enhances metastasis and alters tumor metabolism. Cell. 2016;176:100-114.","journal-title":"Cell"},{"key":"e_1_3_3_45_2","first-page":"613","article-title":"MDM4 overexpression as a potential therapeutic target in cancer","volume":"19","author":"Wang Y","year":"2019","unstructured":"Wang Y, Hou Y, Zhang H, et al. MDM4 overexpression as a potential therapeutic target in cancer. Nat Rev Cancer. 2019;19:613-624.","journal-title":"Nat Rev Cancer"}],"container-title":["Clinical Medicine Insights: Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/11795549251352047","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/11795549251352047","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/11795549251352047","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T03:40:12Z","timestamp":1777693212000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/11795549251352047"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,3]]},"references-count":44,"alternative-id":["10.1177\/11795549251352047"],"URL":"https:\/\/doi.org\/10.1177\/11795549251352047","relation":{},"ISSN":["1179-5549","1179-5549"],"issn-type":[{"value":"1179-5549","type":"print"},{"value":"1179-5549","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,3]]},"article-number":"11795549251352047"}}